Table 5.

Frequencies and prevalence of seropositive tests stratified according to baseline characteristics.

	Frequencies	Prevalence (95%CI)	Test performance-adjusted prevalence (95%CI)
Sex
Female	126/702	17.95(15.2–21)	24.84(20.6–29.5)
Male	214/1363	15.7(13.8–17.7)	21.39(18.5–24.5)
Age categories
<30	61/439	13.9(10.8–17.5)	18.61(13.8–24.1)
30–39	135/839	16.09(13.7–18.8)	21.99(18.3–26.1)
40–49	92/496	18.55(15.2–22.3)	25.77(20.7–31.5)
50–59	38/222	17.12(12.4–22.7)	23.56(16.3–32.2)
≥60	7/27	25.93(11.1–46.3)	37.12(14.3–68.4)
BMI categories
≤ 25	149/1,058	14.08(12–16.3)	18.9(15.8–22.3)
25.1–30	147/757	19.42(16.7–22.4)	27.11(22.9–31.7)
>30	37/217	17.05(12.3–22.7)	23.46(16.2–32.2)
Comorbidity
No	254/1,557	16.31(14.5–18.2)	22.33(19.6–25.3)
Yes	85/500	17.0(13.8–20.6)	23.38(18.5–28.9)
Diagnosed COVID−19
No	46/313	14.7(11–19.1)	19.84(14.1–26.6)
Yes	60/108	55.56(45.7–65.1)	82.7(67.5–97.4)
Contact with patients with COVID−19
No	53/433	12.24(9.3–15.7)	16.06(11.5–21.4)
Yes	287/1,632	17.59(15.8–19.5)	24.29(21.5–27.3)
Symptoms
Asymptomatic	60/629	9.54(7.4–12.1)	11.91(8.6–15.9)
(0)
Paucisymptomatic	91/716	12.71(10.4–15.4)	16.78(13.2–20.9)
(1–3)
Symptomatic	184/708	25.99(22.8–29.4)	37.21(32.3–42.4)
(≥4)